RxDoctor Payments Data

Dmitriy Elkin, MD

Internal Medicine · Far Rockaway, NYNPI 1760431761

Payments from drug & device makers

$10,423in general payments, 2019–2025

Across 658 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$710
  • Novo Nordisk$642
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$543
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,33599%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,423 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$750,057
Medicare patients
934
Services billed
10,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban363$204,525
JanuviaSitagliptin Phosphate339$164,421
JardianceEmpagliflozin237$141,872
OzempicSemaglutide115$132,862
LinzessLinaclotide178$114,056
TrulicityDulaglutide101$109,540
Invega SustennaPaliperidone Palmitate32$106,036
Clemastine Fumarate13$101,604
TradjentaLinagliptin204$97,673
Trijardy XrEmpaglifloz/Linaglip/Metformin136$94,675
XareltoRivaroxaban196$92,953
ZenpepLipase/Protease/Amylase61$85,110
Repatha SureclickEvolocumab150$84,556
CreonLipase/Protease/Amylase69$73,968
JanumetSitagliptin Phos/Metformin Hcl151$73,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Jentadueto, Combivent Respimat$308$364,301631 claims
MerckJanuvia, Janumet$136$237,734490 claims
Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta$250$212,141248 claims
AbbVieLinzess, Creon, Namzaric$1,850$211,135285 claims
PfizerEliquis$415$204,525363 claims
Novo NordiskOzempic, Rybelsus$642$173,132150 claims
Lilly USA, LLCTrulicity, Mounjaro$710$137,568122 claims
NovartisEntresto$479$63,409130 claims
Astellas Pharma US IncMyrbetriq$49$61,600126 claims
AmgenProlia$1,474$55,15132 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$12$51,00821 claims
GSKTrelegy Ellipta, Incruse Ellipta$289$48,52887 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Far Rockaway

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →